GlassScriptPhysician profile
Buelah L Powell
NPI 1760803365
$3,122.33
in general payments reported to CMS, 2019-2025
28 companies · $710 in 2025
The $710 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $514 · 2023: $856 · 2024: $462 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.45 |
| Education | $327.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,016.70 | 2021-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $301.95 | 2021-2024 | Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $284.13 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar, INC. | $268.07 | 2023-2025 | Jatenzo |
| Urogen Pharma, INC. | $201.51 | 2022-2025 | Jelmyto |
| Antares Pharma, INC. | $114.50 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Myriad Genetic Laboratories, INC. | $103.85 | 2021-2023 | Prolaris |
| Abc Home Medical Supply, INC. | $83.19 | 2022-2025 | |
| Urovant Sciences INC | $81.64 | 2022 | |
| Teleflex LLC | $76.15 | 2021 | |
| Ferring Pharmaceuticals INC. | $75.33 | 2024-2025 | Adstiladrin |
| Civco Medical Instruments | $74.05 | 2024-2025 | |
| Boston Scientific Corporation | $49.60 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $41.08 | 2022-2025 | Exparel |
| Acerus Pharmaceuticals Corporation | $35.41 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $33.24 | 2023 | Pylarify |
| Halozyme INC | $33.12 | 2023 | |
| Hollister Incorporated | $30.71 | 2023 | Onli, Vapro Pocket, Infyna Chic |
| Immunitybio, INC. | $30.70 | 2025 | |
| Cycle Pharmaceuticals INC | $28.57 | 2024 | Tiopronin |
| Tolmar Pharmaceuticals, INC. | $21.88 | 2021 | |
| Myovant Sciences INC. | $21.57 | 2021 | |
| Endo USA, INC. | $21.37 | 2024 | Aveed, Xiaflex |
| Endo Pharmaceuticals INC. | $20.20 | 2021 | |
| Dentsply Ih INC. | $20.16 | 2022 | |
| Clarus Therapeutics INC. | $19.61 | 2021 | |
| Abbvie INC. | $19.04 | 2022 | |
| Axonics, INC. | $15.00 | 2024 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buelah Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.